Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma. (Q42704678)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 August 2014

Language	Label	Description	Also known as
English	Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.	scientific article published on 8 August 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Stéphanie Lheureux

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Monique N'Diaye

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Cécile Blanc-Fournier

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Audrey Emmanuelle Dugué

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Bénédicte Clarisse

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Florence Giffard

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Edwige Abeilard

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Mélanie Briand

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alexandre Labiche

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jean-Michel Grellard

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Hubert Crouet

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sandrine Martin

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Laurent Poulain

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

0 references

publication date

8 August 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

136

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

E340-50

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25066666%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Bcl-2 modulation to activate apoptosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Mcl-1; the molecular regulation of protein function

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Latest research and treatment of advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Apoptosis in targeted therapy responses: the role of BIM.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Targeting the B-cell lymphoma/leukemia 2 family in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Decoding and unlocking the BCL-2 dependency of cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Many players in BCL-2 family affairs

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29104

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42704678&oldid=1581240350"